Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Sanofi ( (SNY) ) is now available.
On February 10, 2026, Sanofi completed its acquisition of U.S.-based Dynavax Technologies Corporation, bringing into its portfolio the marketed adult hepatitis B vaccine HEPLISAV-B and early-stage shingles vaccine candidate Z-1018, along with additional vaccine pipeline assets. The all-cash deal, executed via a tender offer and follow-on merger at $15.50 per share, strengthens Sanofi’s position in adult immunization by pairing Dynavax’s products and candidates with Sanofi’s global commercial scale, and results in Dynavax becoming an indirect wholly owned subsidiary and delisting from the Nasdaq Global Select Market as of that date.
The most recent analyst rating on (SNY) stock is a Hold with a $51.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
The score is driven primarily by solid financial resilience and a constructive earnings outlook (growth, margin expansion, and buybacks). Valuation is supportive with a reasonable P/E and strong dividend, while weaker technical trend signals (below major moving averages and negative MACD) temper the overall rating.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is an R&D-driven, AI-powered biopharmaceutical company focused on discovering and developing medicines and vaccines that leverage its expertise in the immune system. The group markets treatments and preventive vaccines to millions of patients worldwide and is listed in Paris on Euronext under the symbol SAN and on Nasdaq under the symbol SNY.
Average Trading Volume: 3,015,549
Technical Sentiment Signal: Hold
Current Market Cap: $115.9B
For detailed information about SNY stock, go to TipRanks’ Stock Analysis page.
